News
DGAP-News: Abivax 2022 Financial Communication Calendar
DGAP-News: Abivax 2022 Financial Communication Calendar
ALTHEORA: Strong acceleration of activity in 2021: +15% - 2022 Orders: +16%
ALTHEORA: Strong acceleration of activity in 2021: +15% - 2022 Orders: +16%
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax präsentiert die Ergebnisse der klinischen Phase 1/2 Studie mit ABX196 zur Behandlung von Leberkrebs am 21. Januar auf dem ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
Kaufman & Broad SA: UPDATE ON THE AUSTERLITZ TRAIN STATION PROJECT
Kaufman & Broad SA: UPDATE ON THE AUSTERLITZ TRAIN STATION PROJECT
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
DGAP-News: Abivax: Ergebnis der wissenschaftlichen Beratungen der europ. Arzneimittelbehörde (EMA) unterstützt die Überführung von ABX464 in die klinische Phase-3-Testung zur Behandlung von Colitis ulcerosa
Correction of a release from 07.01.2022 16:10 CET/CEST - Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA
Correction of a release from 07.01.2022 16:10 CET/CEST - Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA
RUBIS: Half-year statement on Rubis' liquidity agreement with Exane BNP Paribas
RUBIS: Half-year statement on Rubis' liquidity agreement with Exane BNP Paribas
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA
Kaufman & Broad SA: HALF-YEAR LIQUIDITY CONTRACT STATEMENT FOR KAUFMAN & BROAD SA
ALD PROPOSED ACQUISITION OF LEASEPLAN Creation of a leading global player in mobility
ALD PROPOSED ACQUISITION OF LEASEPLAN Creation of a leading global player in mobility
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
ROCTOOL: Decathlon, with its design & industrialization teams, launches its first production of 'Eco-Molded' helmets with Roctool technology
ROCTOOL: Decathlon, with its design & industrialization teams, launches its first production of 'Eco-Molded' helmets with Roctool technology
RUBIS: Information relating to the total number of voting rights and shares as of 12/31/2021
RUBIS: Information relating to the total number of voting rights and shares as of 12/31/2021
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
RUBIS BECOMES AN INTEGRATED MULTI-ENERGY GROUP WITH THE ACQUISITION OF PHOTOSOL, A LEADING FRENCH SOLAR ENERGY PLAYER
RUBIS BECOMES AN INTEGRATED MULTI-ENERGY GROUP WITH THE ACQUISITION OF PHOTOSOL, A LEADING FRENCH SOLAR ENERGY PLAYER
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference